Literature DB >> 29099677

Novel Latency Reversal Agents for HIV-1 Cure.

Adam M Spivak1, Vicente Planelles2.   

Abstract

Antiretroviral therapy (ART) has rendered HIV-1 infection a treatable illness; however, ART is not curative owing to the persistence of replication-competent, latent proviruses in long-lived resting T cells. Strategies that target these latently infected cells and allow immune recognition and clearance of this reservoir will be necessary to eradicate HIV-1 in infected individuals. This review describes current pharmacologic approaches to reactivate the latent reservoir so that infected cells can be recognized and targeted, with the ultimate goal of achieving an HIV-1 cure.

Entities:  

Keywords:  HIV-1 reservoir; NF-κB; SMAC; STAT5; benzotriazole; disulfiram; ingenol; latency reversal agents; protein kinase C; shock and kill; viral latency

Mesh：

Substances：

Year:  2017        PMID： 29099677      PMCID： PMC5892446          DOI： 10.1146/annurev-med-052716-031710

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN： 0066-4219            Impact factor:   13.739


  110 in total

1.  An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription.

Authors:  Guillaume Mousseau; Mark A Clementz; Wendy N Bakeman; Nisha Nagarsheth; Michael Cameron; Jun Shi; Phil Baran; Rémi Fromentin; Nicolas Chomont; Susana T Valente
Journal:  Cell Host Microbe       Date:  2012-07-19       Impact factor: 21.023

2.  A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy.

Authors:  Adam M Spivak; Adriana Andrade; Evelyn Eisele; Rebecca Hoh; Peter Bacchetti; Namandjé N Bumpus; Fatemeh Emad; Robert Buckheit; Elinore F McCance-Katz; Jun Lai; Margene Kennedy; Geetanjali Chander; Robert F Siliciano; Janet D Siliciano; Steven G Deeks
Journal:  Clin Infect Dis       Date:  2013-12-12       Impact factor: 9.079

3.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

Review 4.  Targeting HIV latency: pharmacologic strategies toward eradication.

Authors:  Sifei Xing; Robert F Siliciano
Journal:  Drug Discov Today       Date:  2012-12-25       Impact factor: 7.851

5.  HIV-1 Latency-Reversing Agents Prostratin and Bryostatin-1 Induce Blood-Brain Barrier Disruption/Inflammation and Modulate Leukocyte Adhesion/Transmigration.

Authors:  Clélia Dental; Alizé Proust; Michel Ouellet; Corinne Barat; Michel J Tremblay
Journal:  J Immunol       Date:  2016-12-19       Impact factor: 5.422

6.  Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.

Authors:  Sifei Xing; Cynthia K Bullen; Neeta S Shroff; Liang Shan; Hung-Chih Yang; Jordyn L Manucci; Shridhar Bhat; Hao Zhang; Joseph B Margolick; Thomas C Quinn; David M Margolis; Janet D Siliciano; Robert F Siliciano
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

7.  Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system.

Authors:  Thomas A Rasmussen; Martin Tolstrup; Holger Jon Møller; Christel R Brinkmann; Rikke Olesen; Christian Erikstrup; Alex L Laursen; Lars Østergaard; Ole S Søgaard
Journal:  Open Forum Infect Dis       Date:  2015-03-30       Impact factor: 3.835

8.  HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function.

Authors:  Carolina Garrido; Adam M Spivak; Natalia Soriano-Sarabia; Mary Ann Checkley; Edward Barker; Jonathan Karn; Vicente Planelles; David M Margolis
Journal:  Front Immunol       Date:  2016-09-21       Impact factor: 7.561

9.  The effect of Ingenol-B on the suppressive capacity of elite suppressor HIV-specific CD8+ T cells.

Authors:  Abena K Kwaa; Kennedy Goldsborough; Victoria E Walker-Sperling; Luiz F Pianowski; Lucio Gama; Joel N Blankson
Journal:  PLoS One       Date:  2017-05-03       Impact factor: 3.240

10.  Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation.

Authors:  Mohamed Abdel-Mohsen; Leonard Chavez; Ravi Tandon; Glen M Chew; Xutao Deng; Ali Danesh; Sheila Keating; Marion Lanteri; Michael L Samuels; Rebecca Hoh; Jonah B Sacha; Philip J Norris; Toshiro Niki; Cecilia M Shikuma; Mitsuomi Hirashima; Steven G Deeks; Lishomwa C Ndhlovu; Satish K Pillai
Journal:  PLoS Pathog       Date:  2016-06-02       Impact factor: 6.823
View more
  71 in total

Review 1.  Current and Future Therapeutic Strategies for Lentiviral Eradication from Macrophage Reservoirs.

Authors:  Tiffany A Peterson; Andrew G MacLean
Journal:  J Neuroimmune Pharmacol       Date:  2018-10-13       Impact factor: 4.147

Review 2.  Barriers for HIV Cure: The Latent Reservoir.

Authors:  Sergio Castro-Gonzalez; Marta Colomer-Lluch; Ruth Serra-Moreno
Journal:  AIDS Res Hum Retroviruses       Date:  2018-08-28       Impact factor: 2.205

3.  Nonhuman Primate Testing of the Impact of Different Regulatory T Cell Depletion Strategies on Reactivation and Clearance of Latent Simian Immunodeficiency Virus.

Authors:  Ranjit Sivanandham; Adam J Kleinman; Paola Sette; Egidio Brocca-Cofano; Sindhuja Murali Kilapandal Venkatraman; Benjamin B Policicchio; Tianyu He; Cuiling Xu; Julia Swarthout; Zhirui Wang; Ivona Pandrea; Cristian Apetrei
Journal:  J Virol       Date:  2020-09-15       Impact factor: 5.103

4.  Latency-Reversing Agents Induce Differential Responses in Distinct Memory CD4 T Cell Subsets in Individuals on Antiretroviral Therapy.

Authors:  Marion Pardons; Rémi Fromentin; Amélie Pagliuzza; Jean-Pierre Routy; Nicolas Chomont
Journal:  Cell Rep       Date:  2019-11-26       Impact factor: 9.423

5.  TRIM28 promotes HIV-1 latency by SUMOylating CDK9 and inhibiting P-TEFb.

Authors:  Xiancai Ma; Tao Yang; Yuewen Luo; Liyang Wu; Yawen Jiang; Zheng Song; Ting Pan; Bingfeng Liu; Guangyan Liu; Jun Liu; Fei Yu; Zhangping He; Wanying Zhang; Jinyu Yang; Liting Liang; Yuanjun Guan; Xu Zhang; Linghua Li; Weiping Cai; Xiaoping Tang; Song Gao; Kai Deng; Hui Zhang
Journal:  Elife       Date:  2019-01-17       Impact factor: 8.140

6.  Post-traumatic Stress Disorder, Cocaine Use, and HIV Persistence.

Authors:  Olorunleke Oni; Tiffany R Glynn; Michael H Antoni; Danita Jemison; Allan Rodriguez; Mark Sharkey; Jessica Salinas; Mario Stevenson; Adam W Carrico
Journal:  Int J Behav Med       Date:  2019-10

7.  Thiostrepton Reactivates Latent HIV-1 through the p-TEFb and NF-κB Pathways Mediated by Heat Shock Response.

Authors:  Wen Peng; Zhongsi Hong; Xi Chen; Hongbo Gao; Zhuanglin Dai; Jiacong Zhao; Wen Liu; Dan Li; Kai Deng
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

Review 8.  Immunotherapeutics to Treat HIV in the Central Nervous System.

Authors:  Andrew Kapoor; C Sabrina Tan
Journal:  Curr HIV/AIDS Rep       Date:  2020-10       Impact factor: 5.071

9.  PLGA nanodepots co-encapsulating prostratin and anti-CD25 enhance primary natural killer cell antiviral and antitumor function.

Authors:  Elizabeth E Sweeney; Preethi B Balakrishnan; Allison B Powell; Allan Bowen; Indra Sarabia; Rachel A Burga; R Brad Jones; Alberto Bosque; C Russell Y Cruz; Rohan Fernandes
Journal:  Nano Res       Date:  2020-02-21       Impact factor: 8.897

Review 10.  Targeting the Latent Reservoir for HIV-1.

Authors:  Srona Sengupta; Robert F Siliciano
Journal:  Immunity       Date:  2018-05-15       Impact factor: 31.745
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.